A semisynthetic derivative of CA, 6α-ethyl-23(S)-methylcholic acid (S-MECA, INT777), which acts as a TGR5 agonist, has been shown to improve metabolic syndrome and reduce atherosclerosis in mice. Here, GPBAR1 is linked to atherosclerosis.